ClinicalTrials.gg

Program

mitapivat

Also written as “Mitapivat”, “AG-348” and “Mitapivat tablet”.

Its studies are mostly in beta-Thalassemia · Anemia, Hemolytic · Anemia, Sickle Cell · Anemia · Thalassemia, led by Agios Pharmaceuticals.

Furthest: phase 4, since Mar 9, 202324 company-led studies, 10 open or runningNext primary completion: Mar 2029 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Agios Pharmaceuticals2410 open or runningphase 4since Mar 9, 2023Apr 2, 2014Mar 2029phase 3 · NCT07517133

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 7 studies since Apr 2, 2014.

  1. Sep 10, 2018Phase 2 study in ThalassemiaNCT03692052 · 20 enrolled · United States, Canada, United Kingdom
  2. Feb 22, 2019Phase 3 study in Pyruvate Kinase Deficiency of Red CellsNCT03853798 · 90 enrolled · United States, Brazil, Canada and more
  3. Jul 13, 2020Phase 1 study in Healthy VolunteersNCT04472832 · 32 enrolled · United States
  4. Sep 22, 2020Phase 1 study in Healthy VolunteersNCT04565678 · 32 enrolled · United States
  5. Jan 4, 2021Phase 1 study in Healthy VolunteersNCT04696393 · 26 enrolled · United States
  6. Feb 18, 20212 phase 3 studiesNCT04770779, NCT04770753
  7. Jul 29, 2021Phase 3 study in Anemia, Sickle CellNCT05031780 · 286 enrolled · United States, Belgium, Brazil and more
  8. Nov 22, 20212 phase 3 studies in AnemiaNCT05175105, NCT05144256
  9. Nov 3, 2022Phase 1 study in Moderate Hepatic ImpairmentNCT05610657 · 20 enrolled · United States
  10. Mar 9, 2023Phase 4 study in Pyruvate Kinase Deficiency of Red CellsNCT05777993 · 55 planned · Belgium, Brazil, Canada and more
  11. Feb 23, 2024Phase 2 study in Anemia, Sickle CellNCT06286046
  12. Oct 17, 2024Phase 1 study in Healthy ParticipantsNCT06648824 · 20 enrolled · United States
  13. Mar 26, 20262 phase 3 studiesNCT07517133, NCT07506863
  14. Jun 15, 2026Phase 3 study in Anemia, Sickle CellNCT07656415 · 159 planned · United States

Ahead

  1. Mar 2029Primary completion: phase 3 study in Non-Transfusion-dependent Alpha-ThalassemiaNCT07517133
  2. Jun 2029Primary completion: phase 3 study in Transfusion-dependent Alpha-ThalassemiaNCT07506863
  3. Aug 2029Primary completion: phase 3 study in Anemia, Sickle CellNCT07656415
  4. Aug 2029Primary completion: phase 4 study in Pyruvate Kinase Deficiency of Red CellsNCT05777993

TargetBeta

PKLR →read by rule
“Pyruvate kinase isozymes R/L activator; Pyruvate kinase isozymes R/L activator; Pyruvate kinase isozymes R/L activator”ChEMBL 37, by rule

Other programs on PKLR

ProgramCompanyFurthest phaseStudies
etavopivatNovo Nordiskphase 312

Studies

All 24 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07656415Anemia, Sickle Cell · United States3RecruitingAug 2029159
NCT07517133Non-Transfusion-dependent Alpha-Thalassemia · United States3RecruitingMar 202945
NCT07506863Transfusion-dependent Alpha-Thalassemia · United States3RecruitingJun 202954
NCT06648824Healthy Participants · United States1CompletedDec 3, 202420
NCT06286046Anemia, Sickle Cell2WithdrawnMay 20270
NCT05777993Pyruvate Kinase Deficiency of Red Cells · Belgium, Brazil, Canada and more4By invitationAug 202955
NCT05610657Moderate Hepatic Impairment · United States1CompletedJul 21, 202320
NCT05175105Anemia · United States, Canada, France and more3Active, not recruitingDec 13, 202430
NCT05144256Anemia · United States, Canada, Czechia and more3Active, not recruitingMay 3, 202449
NCT05031780Anemia, Sickle Cell · United States, Belgium, Brazil and more3Active, not recruitingOct 30, 2025286
NCT04770779Transfusion-dependent Alpha-Thalassemia · United States, Brazil, Bulgaria and more3Active, not recruitingApr 11, 2024258
NCT04770753Non-Transfusion-dependent Alpha-Thalassemia · United States, Brazil, Bulgaria and more3Active, not recruitingNov 13, 2023194
NCT04696393Healthy Volunteers · United States1CompletedMar 19, 202126
NCT04565678Healthy Volunteers · United States1CompletedDec 3, 202032
NCT04472832Healthy Volunteers · United States1CompletedNov 23, 202032
NCT03853798Pyruvate Kinase Deficiency of Red Cells · United States, Brazil, Canada and more3CompletedJul 3, 202490
NCT03692052Thalassemia · United States, Canada, United Kingdom2Active, not recruitingAug 20, 202020
NCT03703505Healthy Volunteers · United States1CompletedJun 1, 20188
NCT03548220Pyruvate Kinase Deficiency of Red Cells · United States, Brazil, Canada and more3CompletedOct 9, 202080
NCT03559699Pyruvate Kinase Deficiency of Red Cells · United States, Canada, Denmark and more3CompletedNov 12, 202027
NCT03250598Healthy · United States1CompletedOct 2, 201760
NCT02476916Pyruvate Kinase Deficiency of Red Cells · United States, Canada, France and more2CompletedMay 8, 201752
NCT02149966Healthy Volunteer · United States1CompletedNov 201448
NCT02108106Healthy Volunteer · United States1CompletedAug 201448

How it is read

Names in the registry

  • “Mitapivat”, 13 entries
  • “AG-348”, 10 entries
  • “Mitapivat tablet”, 1 entry
  • “Mitapivat 100 mg”, 1 entry
  • “Mitapivat 300 mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.